blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3914620

EP3914620 - TREATMENT OF T CELL LYMPHOMA [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  30.03.2023
Database last updated on 24.08.2024
FormerRequest for examination was made
Status updated on  29.10.2021
FormerThe international publication has been made
Status updated on  03.08.2020
Formerunknown
Status updated on  03.02.2020
Most recent event   Tooltip29.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Innate Pharma
117, Avenue de Luminy
13009 Marseille / FR
[2021/48]
Inventor(s)01 / ABDELAZIM, Hatem
538 Rue Paradis
13008 Marseille / FR
02 / PATUREL, Carine
411 Allée du Bois
69280 Marcy L'etoile / FR
[N/P]
Former [2021/48]01 / ABDELAZIM, Hatem
13008 Marseille / FR
02 / PATUREL, Carine
69280 Marcy L'etoile / FR
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[N/P]
Former [2021/48]Völlmy, Lukas
Innate Pharma
IP Department
117, avenue de Luminy
13009 Marseille / FR
Application number, filing date20701559.520.01.2020
[2021/48]
WO2020EP51234
Priority number, dateUS201962795194P22.01.2019         Original published format: US 201962795194 P
[2021/48]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020152081
Date:30.07.2020
Language:EN
[2020/31]
Type: A1 Application with search report 
No.:EP3914620
Date:01.12.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 30.07.2020 takes the place of the publication of the European patent application.
[2021/48]
Search report(s)International search report - published on:EP30.07.2020
ClassificationIPC:C07K16/28, A61K31/282, A61K31/7068, A61K39/395, A61P35/00, A61P35/02, G01N33/53
[2021/48]
CPC:
C07K16/2803 (EP,KR,US); A61K39/3955 (KR); A61K31/282 (EP,US);
A61K31/555 (EP,KR); A61K31/7068 (EP,KR,US); A61K33/243 (EP,KR);
A61K39/39558 (EP,US); A61P35/00 (EP,US); A61P35/02 (EP,KR);
G01N33/574 (KR); G01N33/57426 (EP,US); A61K2039/505 (EP,KR,US);
A61K2039/804 (EP); A61K2300/00 (KR); C07K2317/24 (EP,KR);
C07K2317/732 (EP,KR,US); G01N2333/70503 (US); G01N2800/52 (EP,KR) (-)
C-Set:
A61K31/282, A61K2300/00 (EP);
A61K31/555, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP);
A61K33/243, A61K2300/00 (EP);
A61K39/39558, A61K2300/00 (EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/48]
TitleGerman:BEHANDLUNG VON T-ZELL-LYMPHOMEN[2021/48]
English:TREATMENT OF T CELL LYMPHOMA[2021/48]
French:TRAITEMENT DU LYMPHOME À CELLULES T[2021/48]
Entry into regional phase29.07.2021National basic fee paid 
29.07.2021Designation fee(s) paid 
29.07.2021Examination fee paid 
Examination procedure29.07.2021Amendment by applicant (claims and/or description)
29.07.2021Examination requested  [2021/48]
29.07.2021Date on which the examining division has become responsible
29.03.2023Despatch of a communication from the examining division (Time limit: M04)
05.05.2023Reply to a communication from the examining division
Fees paidRenewal fee
27.01.2022Renewal fee patent year 03
27.01.2023Renewal fee patent year 04
29.01.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2014044686  (INNATE PHARMA [FR]) [X] 3-19,21-27 * example 2 * * page 70, line 31 *;
 [X]WO2018073363  (INNATE PHARMA [FR]) [X] 3-19,21-27 * sequences 31, 26, 25 *;
 [A]US2018291102  (GAULARD PHILIPPE [FR], et al) [A] 35* paragraphs [0059] , [0066] , [0008] , [0090] , [0244] , [0261] , [0445] *;
 [XI]  - ARGNANI LISA ET AL, "Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease", CANCER TREATMENT REVIEWS, (20171028), vol. 61, doi:10.1016/J.CTRV.2017.10.007, ISSN 0305-7372, pages 61 - 69, XP085264458 [X] 3-19,27-32,34 * table 1 * * page 66, column right * * both columns; page 64 * [I] 1-17,19-28,30-34

DOI:   http://dx.doi.org/10.1016/j.ctrv.2017.10.007
 [XI]  - PRINCE H MILES ET AL, "Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ELSEVIER, AMSTERDAM, NL, (20180718), vol. 31, no. 3, doi:10.1016/J.BEHA.2018.07.007, ISSN 1521-6926, pages 322 - 335, XP085470247 [X] 3-19,27-32,34 * pages 332, 332 * * paragraph [08.1] * [I] 1-17,19-28,30-34

DOI:   http://dx.doi.org/10.1016/j.beha.2018.07.007
 [X]  - JULIAN A. MARIN-ACEVEDO ET AL, "Next generation of immune checkpoint therapy in cancer: new developments and challenges", JOURNAL OF HEMATOLOGY & ONCOLOGY, (20180315), vol. 11, no. 1, doi:10.1186/s13045-018-0582-8, XP055642850 [X] 3-19,27 * bottom left; page 11 *

DOI:   http://dx.doi.org/10.1186/s13045-018-0582-8
 [X]  - A. MARIE-CARDINE ET AL, "IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma", CANCER RESEARCH, US, (20141101), vol. 74, no. 21, doi:10.1158/0008-5472.CAN-14-1456, ISSN 0008-5472, pages 6060 - 6070, XP055437131 [X] 3-19,27 * the whole document *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-14-1456
 [XI]  - YAO YI-YUN ET AL, "Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma", INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, SPRINGER-VERLAG, INDIA, vol. 33, no. 1, doi:10.1007/S12288-016-0670-2, ISSN 0971-4502, (20160319), pages 74 - 81, (20160319), XP036145702 [X] 33 * abstract * [I] 1-17,19-28,30-34

DOI:   http://dx.doi.org/10.1007/s12288-016-0670-2
 [IP]  - M Cheminant ET AL, "157 KIR3DL2 IS EXPRESSED IN PERIPHERAL T-CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET", Hematological Oncology - Volume 37, Issue S2 Supplement: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18-22 June, 2019, (20190612), pages 204 - 205, URL: https://onlinelibrary.wiley.com/doi/full/10.1002/hon.21_2630, (20200414), XP055685274 [IP] 1-35 * the whole document *
by applicantUS4816567
 US5660827
 WO0042072
 US6162963
 WO0250122
 WO2004032269
 US6737056
 WO2004063351
 WO2004099249
 US6821505
 WO2005047327
 WO2005110474
 WO2005115452
 WO2006088494
 US7122637
 WO2007021841
 US7183387
 WO2007024249
 WO2007106707
 WO2008002933
 US7332581
 US7335742
 US7355008
 US7371826
 US7416727
 WO2008105886
 US7425619
 US7521542
 US7632497
 WO2010081890
 WO2011109400
 WO2014044681
 WO2014044686
 WO2014128221
    - CHOTHIALESK, J. Mol. Biol, (19870000), vol. 196, pages 901 - 917
    - CARIL et al., SIAM J. Applied Math., (19880000), vol. 48, page 1073
    - WANG et al., Nature, (19920000), vol. 355, pages 275 - 278
    - MULLER, Meth. Enzymol., (19830000), vol. 92, pages 589 - 601
    - NICE et al., J. Chroma-togr., (19930000), vol. 646, pages 159 - 168
    - CHOTHIALESK, J. Mol., (19870000), vol. 196, page 901
    - DEVEREUX et al., Nucl. Acid. Res., (19840000), vol. 12, page 387
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410
    - WILLEMZE et al., Blood, (20050000), vol. 105, pages 3768 - 3785
    - OLSEN et al., Blood, (20070000), vol. 110, no. 6, pages 1713 - 1722
    - AGAR et al., J. Clin. Oncol., (20100000), vol. 28, no. 31, pages 4730 - 4739
    - FOSS et al., Blood, (20110000), vol. 117, pages 6756 - 6767
    - PENDE et al., J. Exp. Med., (19960000), vol. 184, pages 505 - 518
    - "Genbank", Database accession no. AAB36593
    - COLONNASAMARIDIS, Science, (19950000), vol. 267, no. 5209, pages 383 - 386
    - REICHMANN et al., Nature, (19880000), vol. 332, page 323
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 103
    - WARD et al., Nature, (19890000), vol. 341, page 544
    - EHRING H, Analytical Biochemistry, (19990000), vol. 267, no. 2, pages 252 - 259
    - ENGEN, J. R.SMITH, D. L., Anal. Chem., (20010000), vol. 73, pages 256A - 265A
    - Ernst Schering Res Found Workshop, (20040000), vol. 44, pages 149 - 67
    - HUANG et al., Journal of Molecular Biology, (19980000), vol. 281, no. 1, pages 61 - 67
    - SAITOPATTERSON, Methods, (19960600), vol. 9, no. 3, pages 516 - 24
    - DOWNARD, J Mass Spectrom, (20000400), vol. 35, no. 4, pages 493 - 503
    - KISELARDOWNARD, Anal Chem., (19990501), vol. 71, no. 9, pages 1792 - 1801
    - WELLS, Proc Natl Acad Sci USA, (19960000), vol. 93, pages 1 - 6
    - FAGERSTAM et al., Journal Of Molecular Recognition, (19900000), vol. 3, pages 208 - 14
    - LEIPERT et al., Angew. Chem. Int. Ed., (19980000), vol. 37, pages 3308 - 3311
    - KROGER et al., Biosensors and Bioelectronics, (20020000), vol. 17, pages 937 - 944
    - SKERRA et al., Curr. Opinion in Immunol., (19930000), vol. 5, page 256
    - PLUCKTHUN, Immunol., (19920000), vol. 130, page 151
    - MORRISON et al., PNAS, (19840000), page 6851
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, page 593
    - VERHOEYEN, Science, vol. 239, page 1534
    - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623
    - CARTER et al., PNAS, (19920000), vol. 89, page 4285
    - JAKOBOVITZ et al., Nature, (19930000), vol. 362, page 255
    - LAZAR et al., Proc. Nat. Acad. Sci. USA, (20060000), vol. 103, no. 11, pages 405 - 410
    - PRESTA, L.G. et al., Biochem. Soc. Trans., (20020000), vol. 30, no. 4, pages 487 - 490
    - SHIELDS, R.L. et al., J. Biol. Chem., (20020000), vol. 277, no. 30, pages 26733 - 26740
    - SHIELDS, R.L. et al., J. Biol. Chem., (20010000), vol. 276, no. 9, pages 6591 - 6604
 WO2013EP69302
 WO2013EP69293
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.